NeRRe Therapeutics Company
Neurokinin treatment for refractory and/or chronic cough. NeRRe Therapeutics is a clinical-stage company developing a unique pipeline of three neurokinin -1 receptor antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction. Their focus with NeRRe’s lead NK-1 antagonist orvepitant is on Refractory or Unexplained Chronic Cough (RUCC).
Technology:
AgeTech Companies
Industry:
Healthcare
Headquarters:
United Kingdom
Founded Date:
2012
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
7
Total Funding:
$47M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series B
Register and Claim Ownership